Furthermore, due to the contribution of PS to immunosuppressive TME, AnxA5 may serve as a potential immune checkpoint inhibitor to enhance the immunogenicity of tumor-antigen specific immunotherapies, particularly following the administration of cytotoxic chemotherapeutics5,24. Here, ANXA5 is linked to neoplasm.